Navigation Links
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Date:9/19/2007

es of Dynavax's HBV vaccine; the other group received three doses of Engerix-B.

Dynavax reported in mid-July 2007, that an international Phase 3 trial in Europe and Canada had completed enrollment. Data from the pivotal Phase 3 trial plus lot-to-lot consistency trials will contribute to a safety database of approximately 4,000 subjects for a planned BLA submission in 2008. Dynavax's HBV vaccine is based on its proprietary immunostimulatory sequence (ISS) that specifically targets Toll-Like Receptor 9 (TLR9) to stimulate an innate immune response. Dynavax's HBV vaccine combines ISS with HBV surface antigen (HBsAg) and is designed to significantly enhance the level, speed and longevity of protection. Dynavax indicates that as a result of its acquisition of Rhein Biotech in April 2006, the company has secured manufacturing capabilities in Dusseldorf, Germany for producing both clinical and initial commercial quantities of the hepatitis B surface antigen component of the vaccine.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our TLR9 agonists are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Our product candidates include: HEPLISAV, a hepatitis B vaccine in Phase 3; TOLAMBA(TM), a ragweed allergy immunotherapy; a therapy for non-Hodgkin's lymphoma (NHL) in Phase 2 and for metastatic colorectal cancer in Phase 1; and a therapy for hepatitis B also in Phase 1. Our preclinical asthma and COPD program is partnered with AstraZeneca. The National Institutes of Health (NIH) partially funds our preclinical work on a vaccine for influenza. Symphony Dynamo,
'/>"/>

SOURCE Dynavax Technologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial
5. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
7. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
8. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
9. InterMune Presents Research on ITMN-191 in Hepatitis C at Digestive Disease Week Meeting
10. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
11. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015   KaloBios Pharmaceuticals, Inc . (Nasdaq: ... innovative therapies to benefit patients with diseases of unmet ... that the U.S. Food and Drug Administration (FDA) has ... KB003, an anti-GM-CSF monoclonal antibody (mAb), in patients with ... now active. The acceptance of this IND ...
(Date:7/29/2015)... 29, 2015  The Perinatal Quality Foundation (PQF) ... of the advantages, limitations and clinically appropriate interpretation ... diagnostic tests for pregnant women and their healthcare ... world,s leading provider of diagnostic information services, is ... through a grant. Through a ...
(Date:7/29/2015)... CAESAREA, Israel , July 29, 2015 /PRNewswire/-- LabStyle Innovations ... was featured in a national broadcast news segment in ... Australia following regulatory and reimbursement approval ... benefits for the 1.2 million Australians living with diabetes. As ... Dario was a great solution for a 13 year old ...
Breaking Medicine Technology:KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 2KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 3KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 4KaloBios Announces FDA Clearance of Investigational New Drug Application for KB003 in Patients with Chronic Myelomonocytic Leukemia 5Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 2Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 3Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening 4LabStyle Innovations' Dario Diabetes Management Solution Featured on 9 News Australia 2LabStyle Innovations' Dario Diabetes Management Solution Featured on 9 News Australia 3
... U.S. Agency for International Development (USAID) continues to provide ... the midst of an expanding humanitarian crisis. An ailing ... the people of Zimbabwe in danger of other health ... supporting emergency Indoor Residual Spraying (IRS) to shore up ...
... high Dk hybrid contact lens manufacturer, announced today the ... fund the development and clinical trials for next-generation hybrid ... efforts globally. De Novo Ventures of Palo Alto, CA, ... round. Bio-Star Private Equity Fund joined Series A and ...
Cached Medicine Technology:USAID Provides Malaria Assistance to Zimbabwe 2SynergEyes, Inc. Raises $13.3 Million in 'Series C' Financing 2
(Date:7/29/2015)... , ... July 29, 2015 , ... Andrzej Klos, M.D., ... Klos, a board-certified pediatrician for nearly 38 years, is motivated each and every day ... commitment to his profession shine alongside his many awards and accolades, which include multiple ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, ... seniors and offers recommendations on how industry, government, and health care experts can ...
(Date:7/29/2015)... ... ... " Core Organizer ” was featured on NewsWatch as part of its monthly AppWatch, ... iOS, Android, and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted ... organized. , Wouldn’t it be great if everyone could be a little more organized? ...
(Date:7/29/2015)... ... July 29, 2015 , ... Angelo’s FabriClean, an area rug cleaning ... damage restoration of carpets and rugs. The company will now reverse the damage caused ... , An overflowing overhead tank, rain leaking through an accidently left open window ...
(Date:7/29/2015)... ... 2015 , ... The report “Atherosclerosis - Pipeline Review, H1 ... slow, progressive disease that may start in childhood. The report strengthens R&D pipelines ... report on Atherosclerosis Pipeline with 78 market data tables and 15 figures, spread ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 2Health News:NJ Top Docs Presents, Dr. Andrzej Klos of Carepoint Health Pediatrics! 3Health News:Vaccination Rates in Older Adults Fall Short of Targets 2Health News:Vaccination Rates in Older Adults Fall Short of Targets 3Health News:Get More Organized with the Core Organizer App 2Health News:Angelo’s FabriClean Now Offers Water Damage Restoration For Residential and Commercial Accounts 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4
... providing high-quality information to professionals in the pharmaceutical ... in Therapy, to be published from 2008. With ... clients in the pharmaceutical, healthcare and biotechnology industries. ... published by Springer Healthcare Communications (SHC), will continue ...
... Advice, about Red Meat and Cancer ... K. Young, M.S., R.D., Vice President, Nutrition, National Cattlemen,s ... Beef Association, DENVER, Oct. 31 ... for consumers.,There are volumes of research about the benefits of red meat in a ...
... partly seasonal * Online advertised vacancies ... over the year gains in advertised ... vacancies, ... Oct. 31 In October there were 4,161,700,online advertised vacancies, a decrease of ...
... viruses have a strong tropism for hepatocytes; viral antigen ... pancreatitis is common in Fulminant hepatic failure but rarely ... acute viral hepatitis over a three year period were ... 7 had acute pancreatitis and 17 had stretching of ...
... Inc. (NTI(R)) (Nasdaq: NTII ), today announced ... GmbH (Merz) for sales,by Merz and its marketing ... Alzheimer,s disease for the quarter ended June 30,2007. ... payments compared to,the same quarter last year, and ...
... 31 Biopure Corporation,(Nasdaq: BPUR ) announced today ... will revert from BPURD to BPUR at the open ... that trade on the OTCBB,will revert to the following ... and BPREL reverting to BPURL. Biopure Corporation ...
Cached Medicine News:Health News:NCBA Statement on 2007 WCRF/AICR Second Expert Report on Food, Nutrition and Physical Activity and the Prevention of Cancer: 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 2Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 3Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 4Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 5Health News:Online Advertised Job Vacancies Dip in October, The Conference Board Reports Today 6Health News:Is it pancreatitis in acute abdominal pain in acute viral hepatitis? 2Health News:Biopure's Stock Symbol Reverts to BPUR 2
AccuSign® DOA Series Opiates Test...
... SureStep™ Drug Screen Tests are available in ... MDMA (Ecstasy). Designed using Microgenics Antibody Technology, ... only point of care immunoassay targeted to ... both MDA and MDEA but no cross-reactivity ...
The SEDITAINER Erythrocyte Sedimentation Rate (ESR) System is for collection of blood specimens for the measurement of ESR within the blood collection tube, using the SEDITAINER ESR Stand....
... NMP22® Test Kit is a quantitative microplate enzyme ... are at risk for rapid recurrence or occult ... voided urine sample and is twice as sensitive ... to improve patient outcome by identifying those patients ...
Medicine Products: